IL49238A - O-aminoethyl trifluoromethyl-phenyl-ketoximes, their preparation and pharmaceutical compositions containing them - Google Patents

O-aminoethyl trifluoromethyl-phenyl-ketoximes, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL49238A
IL49238A IL49238A IL4923876A IL49238A IL 49238 A IL49238 A IL 49238A IL 49238 A IL49238 A IL 49238A IL 4923876 A IL4923876 A IL 4923876A IL 49238 A IL49238 A IL 49238A
Authority
IL
Israel
Prior art keywords
ketoximes
aminoethyl
trifluoromethyl
phenyl
preparation
Prior art date
Application number
IL49238A
Other languages
English (en)
Other versions
IL49238A0 (en
Original Assignee
Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philips Nv filed Critical Philips Nv
Publication of IL49238A0 publication Critical patent/IL49238A0/xx
Publication of IL49238A publication Critical patent/IL49238A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/50Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/58Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/08Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reaction of hydroxylamines with carbonyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL49238A 1975-03-20 1976-03-17 O-aminoethyl trifluoromethyl-phenyl-ketoximes, their preparation and pharmaceutical compositions containing them IL49238A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7503310A NL7503310A (nl) 1975-03-20 1975-03-20 Verbindingen met antidepressieve werking.

Publications (2)

Publication Number Publication Date
IL49238A0 IL49238A0 (en) 1976-05-31
IL49238A true IL49238A (en) 1978-08-31

Family

ID=19823424

Family Applications (1)

Application Number Title Priority Date Filing Date
IL49238A IL49238A (en) 1975-03-20 1976-03-17 O-aminoethyl trifluoromethyl-phenyl-ketoximes, their preparation and pharmaceutical compositions containing them

Country Status (27)

Country Link
US (1) US4085225A (pl)
JP (1) JPS6026776B2 (pl)
AR (2) AR211011A1 (pl)
AT (1) AT340895B (pl)
AU (1) AU505358B2 (pl)
BE (1) BE839744A (pl)
CA (1) CA1076142A (pl)
CH (4) CH626057A5 (pl)
DD (1) DD128332A5 (pl)
DE (1) DE2610886A1 (pl)
DK (1) DK144942C (pl)
ES (1) ES446192A1 (pl)
FI (1) FI61875C (pl)
FR (1) FR2304336A1 (pl)
GB (1) GB1535226A (pl)
GR (1) GR60052B (pl)
HU (1) HU171030B (pl)
IE (1) IE43768B1 (pl)
IL (1) IL49238A (pl)
IT (1) IT1063064B (pl)
MX (1) MX9203723A (pl)
NL (1) NL7503310A (pl)
PL (3) PL100614B1 (pl)
SE (1) SE410312B (pl)
SU (3) SU635867A3 (pl)
YU (1) YU39345B (pl)
ZA (1) ZA761434B (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1110460B (it) * 1977-03-02 1985-12-23 Ciba Geigy Ag Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego
FR2639942B1 (fr) * 1988-12-02 1991-03-29 Sanofi Sa Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
US5665756A (en) * 1994-08-03 1997-09-09 Hoechst Marion Roussel, Inc. Aminoalkyloximes useful in the treatment of depression and obsessive compulsive disorders
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
DK0759299T3 (da) * 1995-08-16 2000-08-07 Lilly Co Eli Potensering af serotoninrespons
IN182588B (pl) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
IN186677B (pl) 1999-11-12 2001-10-20 Sun Pharmaceutical Ind Ltd
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
EP1276478A2 (en) 2000-04-24 2003-01-22 ARYx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
US7256191B2 (en) * 2000-04-24 2007-08-14 Aryx Therapeutics Materials and methods for the treatment of depression
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
MXPA04003358A (es) * 2001-10-12 2004-07-08 Serenix Pharmaceuticals Llc Antagonistas de vasopresina v1a de ?-lactamilo.
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
AU2004271800A1 (en) 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
ES2515092T3 (es) 2003-12-11 2014-10-29 Sunovion Pharmaceuticals Inc. Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5-ht2c激动剂的用途
AU2006239897A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
CN101175740A (zh) 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
SG163588A1 (en) * 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
CA2615813C (en) * 2005-07-19 2015-12-15 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
JP4615470B2 (ja) * 2006-03-29 2011-01-19 卓郎 簑和田 大脳の認知力を用いた疾患治療・予防の方法および医薬
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2735411T3 (es) 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN107007596A (zh) 2010-07-01 2017-08-04 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
EP2981518B1 (en) 2013-04-03 2021-03-03 ZCL Chemicals Ltd. "an improved process for the preparation of fluvoxamine maleate"
CN106456578B (zh) 2014-02-07 2020-02-18 匈牙利科学院大学及其他机构附属研究所 Sigma-1受体激动剂化合物的用途
NZ724718A (en) 2014-03-28 2023-04-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
CA2960253A1 (en) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2018096376A1 (en) 2016-11-24 2018-05-31 Mta Támogatott Kutatócsoportok Irodája Compositions for organ preservation
WO2019055913A1 (en) 2017-09-15 2019-03-21 Azevan Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692835A (en) * 1967-04-05 1972-09-19 Jan Van Dijk Pharmacologically active amino-ethyl oximes

Also Published As

Publication number Publication date
YU71476A (en) 1982-10-31
CH626057A5 (pl) 1981-10-30
SU620206A3 (ru) 1978-08-15
SE7603341L (sv) 1976-09-21
ZA761434B (en) 1977-10-26
NL7503310A (nl) 1976-09-22
AR211011A1 (es) 1977-10-14
JPS51125345A (en) 1976-11-01
DE2610886C2 (pl) 1987-09-24
YU39345B (en) 1984-10-31
BE839744A (fr) 1976-09-20
DK144942C (da) 1982-12-06
FR2304336A1 (fr) 1976-10-15
IL49238A0 (en) 1976-05-31
IT1063064B (it) 1985-02-11
PL101951B1 (pl) 1979-02-28
DE2610886A1 (de) 1976-10-07
FI760699A7 (pl) 1976-09-21
US4085225A (en) 1978-04-18
GB1535226A (en) 1978-12-13
DK115976A (da) 1976-09-21
FI61875C (fi) 1982-10-11
HU171030B (hu) 1977-10-28
AU505358B2 (en) 1979-11-15
ES446192A1 (es) 1977-10-01
AU1214776A (en) 1977-09-22
FI61875B (fi) 1982-06-30
ATA195476A (de) 1977-05-15
GR60052B (en) 1978-04-04
SE410312B (sv) 1979-10-08
SU645559A3 (ru) 1979-01-30
AR211153A1 (es) 1977-10-31
CH629184A5 (de) 1982-04-15
AT340895B (de) 1978-01-10
PL100614B1 (pl) 1978-10-31
MX9203723A (es) 1992-07-01
IE43768B1 (en) 1981-05-20
DK144942B (da) 1982-07-12
JPS6026776B2 (ja) 1985-06-25
CA1076142A (en) 1980-04-22
PL100052B1 (pl) 1978-08-31
FR2304336B1 (pl) 1979-09-28
DD128332A5 (de) 1977-11-09
IE43768L (en) 1976-09-20
SU635867A3 (ru) 1978-11-30
CH629477A5 (de) 1982-04-30
CH629761A5 (de) 1982-05-14

Similar Documents

Publication Publication Date Title
IL49238A (en) O-aminoethyl trifluoromethyl-phenyl-ketoximes, their preparation and pharmaceutical compositions containing them
IL50632A (en) Pyridinyl-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
IL50176A0 (en) Novel tetrahydroisoquinoline derivatives,their preparation and pharmaceutical compositions containing them
IL48835A0 (en) New peptides,their preparation and pharmaceutical compositions containing them
IL50815A0 (en) New aminobenzoamides their preparation and pharmaceutical compositions containing them
IL49911A0 (en) New 5-aroylpyrrole derivatives,their preparation and pharmaceutical compositions containing them
IL50047A0 (en) Novel peptides,their preparation and pharmaceutical compositions containing them
IL50631A0 (en) 1-benzazolylalkyl-4-substituted-piperidines,their preparation and pharmaceutical compositions containing them
IL50690A0 (en) Novel benzisothiazole derivatives,their preparation and pharmaceutical compositions containing them
IL50869A (en) Heterocyclylthio-ethylimidazole derivatives,their preparation and pharmaceutical compositions containing them
IL49424A0 (en) 1,1,1-triaryl-alkylamines,their preparation and pharmaceutical compositions containing them
IL49788A0 (en) 11-desoxy-16-aryloxy-omega-pentanorprostaglandins,their preparation and pharmaceutical compositions containing them
IL49280A0 (en) Novel benzophenones,their preparation and pharmaceutical compositions containing them
IL50335A (en) Diphenylalkylpolyamine derivatives,their preparation and pharmaceutical compositions containing them
IL49991A (en) L-pyroglutamyl-l-prolinamide, its preparation and pharmaceutical compositions containing it
IL49132A (en) 16,1l-disubstituted androst-4-en-3-ones,their preparation and pharmaceutical compositions containing them
IL50156A (en) N,n-bis-isoquinolinoalkylamine derivatives, their preparation and pharmaceutical compositions containing them
IL50797A0 (en) New penicillins,their preparation and pharmaceutical compositions containing them
IL49099A (en) Xanthene-9-carboxylates, their preparation and pharmaceutical compositions containing them
IL49971A0 (en) New 2-benzoypranone derivatives,their preparation and pharmaceutical compositions containing them
IL48788A0 (en) New penicillins,their preparation and pharmaceutical compositions containing them
IL50554A (en) 2,9-dioxatricyclodecanes,their preparation and pharmaceutical compositions containing them
IL49847A0 (en) New penicillins,their preparation and pharmaceutical compositions containing them
IL49239A (en) O-aminoethyl methylthiophenyl-ketoximes, their preparation and pharmaceutical compositions containing them
IL50090A0 (en) New quinolines,their preparation and pharmaceutical compositions containing them